CLINICAL TRIAL
Published on 04 Feb 2025
Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
doi 10.3389/fimmu.2025.1491448
- 221 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Immunology and Immunotherapy of Skin Cancer
Immunology and Immunotherapy of Skin Cancer
4,281
Total downloads
16k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
SYSTEMATIC REVIEW
Published on 31 Jan 2025
Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis
doi 10.3389/fimmu.2025.1524945
- 505 views
ORIGINAL RESEARCH
Accepted on 29 Jan 2025
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status
doi 10.3389/fimmu.2025.1536642
ORIGINAL RESEARCH
Accepted on 27 Jan 2025
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg
doi 10.3389/fimmu.2025.1509886
REVIEW
Published on 24 Jan 2025
From actinic keratosis to cutaneous squamous cell carcinoma: the key pathogenesis and treatments
doi 10.3389/fimmu.2025.1518633
- 302 views
ORIGINAL RESEARCH
Published on 06 Jan 2025
SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells
doi 10.3389/fimmu.2024.1490821
- 564 views
BRIEF RESEARCH REPORT
Published on 05 Dec 2024
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
doi 10.3389/fimmu.2024.1495004
- 489 views
REVIEW
Published on 04 Dec 2024
The role of circulating tumor DNA in melanomas of the uveal tract
doi 10.3389/fimmu.2024.1509968
- 661 views
ORIGINAL RESEARCH
Published on 04 Sep 2024
A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)
doi 10.3389/fonc.2024.1385685
- 1,066 views
REVIEW
Published on 16 Jul 2024
Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review
doi 10.3389/fonc.2024.1400193
- 1,896 views
- 1 citation
ORIGINAL RESEARCH
Published on 12 Jul 2024
Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab)
doi 10.3389/fimmu.2024.1408667
- 1,999 views
ORIGINAL RESEARCH
Published on 10 Jun 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
doi 10.3389/fimmu.2024.1395225
- 1,214 views
Published in
Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Vaccines and Molecular Therapeutics
- Antigen Presenting Cell Biology
- T Cell Biology
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted:
Impact
- 16kTopic views
- 11kArticle views
- 4,281Article downloads